Engineering an fgfr4 knockout zebrafish to study its role in development and disease
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0310100 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Emma N Harrison und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Childhood Cancer, Nationwide Children's Hospital, Columbus, OH, United States of America. Hauptthemen laut MEDLINE: Zebrafish, Receptor, Fibroblast Growth Factor, Type 4, CRISPR-Cas Systems, Gene Knockout Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Alex's Lemonade Stand Foundation for Childhood Cancer.
Abstract (Originalsprache)
Fibroblast growth factor receptor 4 (FGFR4) has a role in many biological processes, including lipid metabolism, tissue repair, and vertebrate development. In recent years, FGFR4 overexpression and activating mutations have been associated with numerous adult and pediatric cancers. As such, FGFR4 presents an opportunity for therapeutic targeting which is being pursued in clinical trials. To understand the role of FGFR4 signaling in disease and development, we generated and characterized three alleles of fgfr4 knockout zebrafish strains using CRISPR/Cas9. To generate fgfr4 knockout crispants, we injected single-cell wildtype zebrafish embryos with fgfr4 targeting guide RNA and Cas9 proteins, identified adult founders, and outcrossed to wildtype zebrafish to create an F1 generation. The generated mutations introduce a stop codon within the second Ig-like domain of Fgfr4, resulting in a truncated 215, 223, or 228 amino acid Fgfr4 protein compared to 922 amino acids in the full-length protein. All mutant strains exhibited significantly decreased fgfr4 mRNA expression during development, providing evidence for successful knockout of fgfr4 in mutant zebrafish. We found that, consistent with other Fgfr4 knockout animal models, the fgfr4 mutant fish developed normally; however, homozygous fgfr4 mutant zebrafish were significantly smaller than wildtype fish at three months post fertilization. These fgfr4 knockout zebrafish lines are a valuable tool to study the role of FGFR4 in vertebrate development and its viability as a potential therapeutic target in pediatric and adult cancers, as well as other diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Childhood Cancer, Nationwide Children's Hospital, Columbus, OH, United States of America.
- Department of Molecular Genetics, The Ohio State University, Columbus, OH, United States of America.
- Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX, United States of America.
- Department of Pediatrics, The Ohio State University, Columbus, OH, United States of America.
ORCID-Profile: Emma N Harrison, Talia P Sukienik, Collette A LaVigne, Genevieve C Kendall
Förderung
- NCI NIH HHS
- National Cancer Institute
- Alex's Lemonade Stand Foundation for Childhood Cancer
- Ohio State University
- V Foundation for Cancer Research
Zitieren
APA
Harrison, E. N., Jay, A. N., Kent, M. R., Sukienik, T. P., LaVigne, C. A., & Kendall, G. C. (2024). Engineering an fgfr4 knockout zebrafish to study its role in development and disease. PLOS ONE. https://doi.org/10.1371/journal.pone.0310100
Vancouver
Harrison EN, Jay AN, Kent MR, Sukienik TP, LaVigne CA, Kendall GC. Engineering an fgfr4 knockout zebrafish to study its role in development and disease. PLOS ONE. 2024. doi:10.1371/journal.pone.0310100
BibTeX
@article{Harrison2024,
author = {Harrison, Emma N and Jay, Amanda N and Kent, Matthew R and Sukienik, Talia P and LaVigne, Collette A and Kendall, Genevieve C},
title = {Engineering an fgfr4 knockout zebrafish to study its role in development and disease},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0310100}
}
EUVIMED